Tag: Diabetes: Drugs
Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM
Higher proportion of participants achieved HbA1c levels below 6.5 percent with canagliflozin versus placebo
Glipizide Linked to Highest MACE-4 Risk in Individuals With Type 2 Diabetes
Highest risk seen with glipizide versus other sulfonylureas and DPP4 inhibitors as second-line therapy
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
Risk ratios were 1.27 and 1.55 for GERD and its complications during a median follow-up of three years for GLP-1 RA versus SGLT-2 inhibitor users
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls
Common Medications Tied to Older Age at Onset of Parkinson Disease
Almost 10-year delay seen for patients who were started on adrenergic blockers before onset of PD symptoms
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Authors say large, multisite study should provide reassurance for short-term risk
Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level
Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM
Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults
Long-Term Sulfonylurea Use Tied to Impaired Awareness of Hypoglycemia
Odds are lessened with regular diabetes-related medical care
ACP: Recommendations Developed for Newer Type 2 Diabetes Medications
Strong recommendation given for addition of SGLT-2 or GLP-1 agonist to metformin and lifestyle modifications
